Post job

Horizon Pharma USA, Inc. main competitors are Salix Pharmaceuticals, Sagent Pharmaceuticals, and Merck.

Competitor Summary. See how Horizon Pharma USA, Inc. compares to its main competitors:

  • Merck has the most employees (74,000).
  • Employees at Salix Pharmaceuticals earn more than most of the competitors, with an average yearly salary of $106,558.
  • The oldest company is Shionogi, founded in 1878.
Work at Horizon Pharma USA, Inc.?
Share your experience

Horizon Pharma USA, Inc. vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2005
4.6
Deerfield, IL7$25.0M30
1891
4.6
Kenilworth, NJ31$64.2B74,000
2008
4.1
Ann Arbor, MI1$332.3M218
1995
4.3
New York, NY1$115.5M43
2007
4.2
Schaumburg, IL1$318.3M440
1997
4.7
Bothell, WA3$2.0B900
2004
4.3
West Chester, PA1$8.6M71
1996
4.5
San Diego, CA1$218.0M290
2000
4.3
Newport, KY1$18.8M100
Odyssey Pharmaceuticals Inc
2000
3.7
East Hanover, NJ1$6.2M9
2011
3.9
Alpharetta, GA1$11.0M206
2008
3.4
Cranford, NJ1$85.0M125
2006
4.6
Atlanta, GA1$175.0M157
2005
4.8
Parsippany-Troy Hills, NJ2$9.0B15,348
1998
4.7
Deerfield, IL14$12.1B30,481
1996
3.8
Morristown, NJ1$146.1M171
1878
4.4
Florham Park, NJ2$50.0M6,082
1985
4.3
Fairfield, NJ1$145.0M300
1989
4.2
Raleigh, NC2$1.1B1,000
2002
3.1
Ridgeland, MS1$4.3M25
2013
3.9
Roswell, GA1$5.0M222

Rate Horizon Pharma USA, Inc.'s competitiveness in the market.

Zippia waving zebra

Horizon Pharma USA, Inc. salaries vs competitors

Among Horizon Pharma USA, Inc. competitors, employees at Salix Pharmaceuticals earn the most with an average yearly salary of $106,558.

Compare Horizon Pharma USA, Inc. salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Horizon Pharma USA, Inc.
$81,886$39.37-
Merck
$90,328$43.43-
Esperion Therapeutics
$75,747$36.42-
SIGA Technologies
$71,494$34.37-
Sagent Pharmaceuticals
$102,033$49.05-
Seagen
$85,008$40.87-

Compare Horizon Pharma USA, Inc. job title salaries vs competitors

CompanyHighest salaryHourly salary
Horizon Pharma USA, Inc.
$95,235$45.79
Esperion Therapeutics
$101,095$48.60
Salix Pharmaceuticals
$100,449$48.29
Merck
$98,284$47.25
Takeda Pharmaceuticals U.S.A., Inc.
$77,428$37.23
Avion Pharmaceuticals
$76,104$36.59
Daiichi Sankyo
$75,293$36.20
Wraser Pharmaceutical
$74,554$35.84
Santarus
$74,381$35.76
Aqua Pharmaceuticals
$73,824$35.49
Shionogi
$73,350$35.26
Pernix Therapeutics Holdings
$73,345$35.26
Arbor Pharmaceuticals
$73,142$35.16
Xanodyne Pharmaceuticals
$73,037$35.11
Sebela Pharmaceuticals
$73,033$35.11
Odyssey Pharmaceuticals Inc
$72,586$34.90
Akrimax Pharmaceuticals
$72,422$34.82
Brad Pharm
$72,231$34.73
SIGA Technologies
$62,933$30.26
Sagent Pharmaceuticals
$61,842$29.73

Do you work at Horizon Pharma USA, Inc.?

Does Horizon Pharma USA, Inc. effectively differentiate itself from competitors?

Horizon Pharma USA, Inc. jobs

Horizon Pharma USA, Inc. demographics vs competitors

Compare gender at Horizon Pharma USA, Inc. vs competitors

Job titleMaleFemale
Shionogi45%55%
Takeda Pharmaceuticals U.S.A., Inc.49%51%
Daiichi Sankyo51%49%
Merck54%46%
Horizon Pharma USA, Inc.55%45%
Arbor Pharmaceuticals55%45%

Compare race at Horizon Pharma USA, Inc. vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
61%13%12%8%5%
9.0
56%16%10%14%4%
9.8
65%10%16%5%4%
7.8
60%15%11%10%4%
9.5
61%14%14%8%4%
9.7
61%13%11%12%4%
9.7

Horizon Pharma USA, Inc. and similar companies CEOs

CEOBio
Sheldon Koenig
Esperion Therapeutics

Sheldon Koenig joined Portola in 2019 and is responsible for leading the Company’s commercial operations. Prior to joining Portola, Mr. Koenig was senior vice president and head of the cardiovascular franchise for Sanofi, where he led the US business operations and global product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck & Co, Inc. where, for more than 25 years, he took on roles of increasing responsibility within the company’s cardiovascular and thrombosis franchises. He has significant overall experience in primary care, specialist, and hospital markets, as well as business development and licensing. Mr. Koenig holds a B.S. from Drexel University and an M.B.A. from Monmouth University.

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

An intuitive leader who engenders a deep level of trust and loyalty while providing a clear vision and business strategy, with a proven track record in the pharmaceutical, generic, biotechnology and consumer product industries. Recognized for entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise, all driving shareholder value. Open to contract C-level and Board of Director positions.

Roger D. Dansey
Seagen

Ken Keller
Daiichi Sankyo

Gary D. Glick
Odyssey Pharmaceuticals Inc

Nathan McCutcheon
Shionogi

Daniel Glassman
Brad Pharm

Horizon Pharma USA, Inc. competitors FAQs

Search for jobs